

Chinese herbal formula QHF inhibits liver cancer cell invasion and migration

TAO CHEN^{1,2}, QUAN WANG^{1,2}, YUNXIAO LI^{1,2}, HEFEI HUANG^{1,2} and WEI HU^{1,2}

¹College of Medical Sciences, China Three Gorges University; ²Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Yichang, Hubei 443002, P.R. China

Received September 12, 2014; Accepted July 17, 2015

DOI: 10.3892/etm.2016.3247

Abstract. The aim of the present study was to observe the effects of the Chinese herbal formula QHF (Q, Qingrejiedu; H, Huoxuehuayu; and F, Fuzhengguben) on the migration and invasion of hepatocellular carcinoma (HCC) HepG2 cells and to elucidate the potential molecular mechanisms involved. HepG2 cells were treated with various concentrations of QHF, and scratch and Transwell® migration assays were used to qualitatively analyze differences in the migration and invasion activity of these cells. Extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) inhibitors were subsequently introduced in order to study the association between QHF and the invasion of HepG2 cells. The protein expression levels of the mitogen-activated protein kinase (MAPK) signaling pathway in HepG2 cells in the presence and absence of QHF were additionally determined using western blot analysis. The results showed that QHF significantly inhibited the proliferation of the HepG2 cells in a concentration-dependent manner, in addition to inhibiting cell movement, which reduced the ability of the cells to invade and migrate. Western blot analysis indicated that the effects of QHF on HCC HepG2 cells after 24 h were to significantly decrease the expression of phosphorylated- (p-)ERK and to increase the expression of p-p38 and p-JNK; however, the total quantity of ERK, p38 and JNK protein remained unchanged. The administration of an inhibitor of ERK altered p38 and JNK expression and promoted the anti-invasion effects of QHF, whereas p38 and JNK inhibitors only partially reversed this effect. The results of the present study indicate, therefore, that QHF is able to inhibit the migratory and invasive activity of HepG2 cells. A possible underlying mechanism involves the activation of the p38 and JNK MAPK signaling pathway and the attenuation of the ERK signaling pathway.

Introduction

According to Traditional Chinese Medicine (TCM), the etiology and pathogenesis of hepatocellular carcinoma (HCC) involves toxic stagnation, stagnation of damp heat, Qi stagnation and blood stasis and Qi deficiency. Results from clinical epidemiological studies indicate that stasis, toxicity and deficiency are pivotally involved in clinical liver cancer syndrome, with deficiency being the most important factor (1). QHF formula is a Chinese herbal medicine that contains extracts from multiple effective antitumor components, which, in combination, exhibit improved antitumor efficacy. QHF exerts the effects of clearing heat and detoxifying (Qingrejiedu), promoting blood circulation and minimizing blood stasis (Huoxuehuayu), and promoting the recovery of physiological function (Fuzhengguben) (2). The most effective compounds and the optimum therapeutic ratio have been determined on the basis of previous literature and animal experiments, which showed that the most effective therapy consists of 800 mg/kg cinobufotalin, 14 mg/kg ginsenoside Rg3, 5.5 mg/kg notoginseng triterpenes and 100 mg/kg mushroom polysaccharide (2,3).

Preliminary experiments have indicated that QHF is effective against liver cancer, inhibits the growth of solid tumors and prolongs survival in mice exhibiting tumors and ascites. On this basis, we previously investigated the efficacy of QHF and chemotherapy against HCC, and the results suggested that QHF, in combination with the chemotherapy drug cisplatin (DDP), could prevent DDP-induced leukocyte reduction and mitigate thymus and spleen atrophy. Furthermore, the combination treatment was shown to be functional in inhibiting liver cancer cell proliferation and increasing the apoptosis of liver cancer cells; G0/G1 phase cells increased while S phase cells decreased (4,5). In preliminary experiments, we found that QHF could inhibit metastasis of liver cancer cells; however, the underlying molecular mechanisms remain unclear.

The aim of the present study was to determine whether QHF inhibits the metastasis of liver cancer cells via its action on the mitogen-activated protein kinase (MAPK) pathway, which modifies signal amplification mechanisms in tumor metastasis. An understanding of the cascade reactions and the expression of genes and their interactions with other signaling pathways may provide novel insights and methods for the clinical treatment of liver cancer metastasis.

Correspondence to: Professor Tao Chen, College of Medical Sciences, China Three Gorges University, 8 University Avenue, Yichang, Hubei 443002, P.R. China
E-mail: chentao140717@sohu.com

Key words: hepatocellular carcinoma, Chinese herbal formula, QHF, invasion, migration, mitogen-activated protein kinase

Materials and methods

Drugs. Huachansu injection (5 ml/dose) was purchased from AnhuiJinchuanBiochemicalCo.,Ltd.(batchno.120811-3;Anhui, China). 20(R)Ginseng saponin Rg3 standard (20 mg/bottle) was obtained from Shanghai Yuanye Biotechnology Co., Ltd. (batch no. 20120506; Shanghai, China). Lentinan standard (1 g/bag) was obtained from Nanjing Zelang Medical Technology Co., Ltd., Nanjing, China). Xuesaitong injection (lyophilized; 400 mg/ampule) was purchased from Kunming Shenghuo Pharmaceutical Group Ltd. (batch no. 12GA12; Kunming, China), and DDP for injection (10 mg/branch) was obtained from Qilu Pharmaceutical Co., Ltd. (batch no. 012027CF; Jinan, China). The QHF preparation contained huachansu, Rg3, notoginseng total saponin and lentinan at a ratio of 57:1:0.4:7.

Reagents and instruments. Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco-BRL (Grand Island, NY, USA). Fetal bovine serum (FBS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Trypsin was obtained from Shanghai Source Leaves Biological Technology, Ltd. (Shanghai, China), and MTT was purchased from Wuhan Boster Biological Technology, Ltd. (Wuhan, China). Matrigel™ glue was obtained from Wuhan Kori Biological Technology, Ltd. (Wuhan, China). A Multiskan™ Spectrum full-wavelength enzyme standard instrument was obtained from Thermo Fisher Scientific (Waltham, MA, USA). An XS-213 optical microscope and a CKX41 inverted phase contrast microscope were purchased from Olympus Corp. (Tokyo, Japan).

Cell line and culture. The human HCC cell line HepG2 was obtained from the China Center for Type Culture Collection of Wuhan University (Wuhan, China). The cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO₂.

MTT assay. An MTT assay was used to detect cell viability following exposure of the HCC cells to QHF. The HepG2 cells were grown on 96-well plates, at a concentration of 2x10³ cells/well, incubated at 37°C in 5% CO₂ for 24 h and then treated with different concentrations of QHF (QHF1-5: 20, 40, 80, 160 and 320 µg/ml). Incubation was subsequently continued for 24, 48 and 72-h periods, respectively (5 wells/treatment group). A total of 20 µl MTT was added 4 h prior to the end of the final incubation time, and the cells were then incubated for a further 4 h. Following incubation, the density value for each well plate was determined using a microplate reader at a detection wavelength of 570 nm.

Cell scratch assay. Using a marker pen and a straight edge guide, lines were drawn evenly across each well on the reverse side of six-well tissue culture plates, with 6 rows per well at 0.5-cm intervals. Next, 1.5x10⁶ cells were aliquoted into each well, and a microscope was used the following day to confirm that each well was coated with cells. A needle was used to scratch and remove the cells from a discrete area of the confluent monolayer. Lines were marked using 10-µl spearheads along

the ruler, perpendicular to the horizontal line scratches. The plates were washed with phosphate-buffered saline three times to remove the displaced scratched cells, and serum-free DMEM was added. Cells exposed to different concentrations of QHF (QHF1-5: 20, 40, 80, 160 and 320 µg/ml) and the appropriate control groups were cultivated simultaneously in an incubator at 37°C in 5% CO₂. At 0 and 24 h, images of the samples were captured, and the procedure was repeated three times.

Cell migration assay. Cell suspensions (100-µl) were sampled from the upper wells and exposed to different QHF concentrations (QHF1-3: 20, 40 and 80 µg/ml). The total volume of fluid in each chamber was 200 µl. A total of 600 µl DMEM containing 10% FBS was placed in each lower chamber and incubated at 37°C in 5% CO₂ for 24 h. Subsequently, the small indoor culture medium was discarded and the cells on the inner surface of the membrane were gently cleaned using cotton. The cells were exposed to 4% paraformaldehyde for 1 h for fixation and stained using crystal violet for 30 min. The cells were then washed with sterile water three times, and the membrane filter was gently placed on a microscope slide using forceps. The outside membrane cells were observed at x200 magnification using an optical microscope, and five fields were randomly selected to calculate an average cell count. This procedure was repeated three times.

Cell invasion assay. Transwell® chambers with a fiber membrane pore size of 8 µm were used. The lower compartment was filled with 600 µl serum media, containing 10% bovine serum albumin (BSA). The upper compartment was filled with 600 µl serum-free media, containing 10% BSA, and 1x10⁵/ml cell suspension was added in a 30-µl volume. The cells were incubated for 24 h at 37°C in a humidified 5% CO₂ atmosphere. The membrane was subsequently removed, fixed using methanol and stained using Giemsa. Five randomly selected fields were counted, and each sample was assayed in duplicate to give an average quantitative measure of the degree of invasiveness of each tumor cell.

Protein extraction and western blot analysis. Cells were collected and washed twice with ice-cold phosphate-buffered saline, prior to lysis with 100 µl radioimmunoprecipitation assay buffer (Takara Biotechnology Co., Ltd., Dalian, China) for 30 min. For nuclear extraction the cells were lysed with Nuclear-Cytosol Extraction kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), according to the manufacturer's instructions. Lysates were centrifuged at 1613 x g for 10 min at 4°C. Total protein content was determined using bicinchoninic acid protein assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). A total of 50 µg of proteins were subjected to 10% SDS-PAGE and transferred to a nitrocellulose membrane (Shanghai Source Leaves Biological Technology Ltd.). The membranes were blocked in Tris-buffered saline + Tween-20 (TBST; Beyotime Institute of Biotechnology, Haimen, China) containing 5% non-fat dried milk for 1 hour at room temperature, and then incubated overnight at 4°C with primary antibodies (1:800 dilution; ERK (cat. no. ab50011); p38 (cat. no. ab31828), JNK (cat. no. ab179461)) against extracellular signal-regulated kinase (ERK) and phosphorylated-(p-)

Table I. Effect of QHF on the proliferation of HepG2 cells.

Group	24 h		48 h		72 h	
	OD	IR (%)	OD	IR (%)	OD	IR (%)
Control	0.3642±0.013	-	0.4071±0.034	-	0.9335±0.028	-
QHF1	0.3112±0.010	14.45	0.3741±0.002	8.10	0.7424±0.038	20.47
QHF2	0.2886±0.009	20.75	0.3721±0.026	8.59	0.6537±0.030	29.97
QHF3	0.2834±0.011	22.18	0.3629±0.031	10.86	0.5505±0.028	41.03
QHF4	0.2369±0.003	34.96	0.3159±0.034	22.38	0.5963±0.018	59.63
QHF5	0.2074±0.021	43.05	0.2602±0.024	36.08	0.2658±0.009	71.53
DDP (5 µg/ml)	0.2857±0.017	21.56	0.2032±0.080	50.07	0.1419±0.011	84.79

Results are presented as the mean ± standard deviation (n=5). OD, optical density; IR, inhibition rate; DDP, cisplatin; QHF1, 20 µg/ml; QHF2, 40 µg/ml; QHF3, 80 µg/ml; QHF4, 160 µg/ml; QHF5, 320 µg/ml.

ERK (both Santa Cruz Biotechnology, Inc.), and p38, c-Jun N-terminal kinase (JNK), p-p38 and p-JNK (all Cell Signaling Technology, Inc., Beverly, MA, USA). The membranes were then washed with TBST three times and incubated with the corresponding secondary antibody (Goat anti-mouse IgG Fc, 1:3000 dilution; cat. no. ab97261; Sigma-Aldrich) for 1 h. The membranes were then washed again and the proteins were visualized using an enhanced chemiluminescence assay kit (Eastman Kodak, Rochester, NY, USA). Images were captured as a permanent record of the data.

Effect of ERK, JNK and p38 inhibitors on the inhibitory effect of QHF on liver cancer cell invasion. The experimental groups were as follows: Blank control, QHF4, QHF4 + JNK inhibitor (SP600125; JNK inhibitor concentration, 10 mM; Beyotime Institute of Biotechnology), QHF4 + p38 inhibitor (SB203580; p38 inhibitor concentration, 10 mM; Beyotime Institute of Biotechnology), QHF4 + ERK inhibitor (PD98059; ERK inhibitor concentration, 10 mM; Selleck Biological Technology, Nanjing, China). The method described for the cell invasion assay was followed.

Statistical analysis. Data are expressed as the mean ± standard deviation and a Student's t-test was performed for the statistical analysis of single comparisons. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

QHF inhibits liver cell proliferation. The results of the MTT assay demonstrated that 24, 48 and 72 h after the exposure of HepG2 cells to different concentrations of QHF, cell proliferation was inhibited in a concentration-dependent manner. As the QHF concentration increased, a more marked inhibitory effect was exerted against HepG2 cell proliferation ($P < 0.05$). A significant difference was observed between the degrees of inhibition produced in each of the groups, although the inhibitory effect was not time-dependent. The inhibition rate in each of the concentration groups after 24 h was not reduced in the groups at 48 h; however, the largest inhibition rate was observed in the groups at 72 h (Table I).




Figure 1. Cell scratch assay at 0 and 24 h. Control at (A) 0 h and (B) 24 h; QHF1 at (C) 0 h and (D) 24 h; QHF2 at (E) 0 h and (F) 24 h; QHF3 at (G) 0 h and (H) 24 h. QHF1, 20 µg/ml; QHF2, 40 µg/ml; QHF3, 80 µg/ml. Magnification, x40.

The effect of QHF on the proliferation of cells within 24 h of exposure to QHF1-QHF3 was limited, with an inhibition




Figure 2. Effect of QHF on HepG2 cell migration in (A) control, (B) QHF1, (C) QHF2 and (D) QHF3 group cells at 24 h (stain, crystal violet; magnification, x200). QHF1, 20 µg/ml; QHF2, 40 µg/ml; QHF3, 80 µg/ml.




Figure 3. Effects of QHF on HepG2 cell invasion in (A) control, (B) QHF1, (C) QHF2 and (D) QHF3 group cells for 24 h (stain, crystal violet; magnification, x200). QHF1, 20 µg/ml; QHF2, 40 µg/ml; QHF3, 80 µg/ml.

rate of 14-22%; therefore, the following three concentrations were selected for subsequent experiments into cell invasion and metastasis.

QHF inhibits the invasion and metastasis of human HCC cells in vitro. An inverted microscope was used to observe the difference in the scratch cell areas of HepG2 cells within 24 h of QHF treatment. The results showed that the scratch damage zones of the QHF intervention groups were significantly reduced compared with those of the control group. In the QHF groups, it was difficult to detect cells migrating to the scratch area; by

contrast, the scratch damage area of the control group was infiltrated with migrated liver cancer cells. These data suggest that QHF is able to inhibit HepG2 cell migration (Fig. 1).

QHF inhibits the migration of HepG2 cells. The cell migration assay results showed that the number of HepG2 cells passing through the membrane filter in the QHF intervention group was significantly reduced compared with that in the control group ($P < 0.05$ or $P < 0.01$), and the migration inhibition rate increased with concentration. It was therefore concluded that QHF exerted a marked concentration-dependent inhibitory effect




Figure 4. ERK and phosphorylated- (p-)ERK protein expression following treatment of HepG2 cells with QHF for 24 h or more. Lanes: A, control; B, QHF1 (20 µg/ml); C, QHF2 (40 µg/ml); D, QHF3 (80 µg/ml); E, QHF4 (160 µg/ml).




Figure 5. p38 and phosphorylated- (p-)p38 protein expression following treatment of HepG2 cells with QHF for 24 h. Lanes: A, control; B, QHF1 (20 µg/ml); C, QHF2 (40 µg/ml); D, QHF3 (80 µg/ml); E, QHF4 (160 µg/ml).




Figure 6. JNK and phosphorylated- (p-)JNK protein expression following treatment of HepG2 cells with QHF for 24 h. Lanes: A, control; B, QHF1 (20 µg/ml); C, QHF2 (40 µg/ml); D, QHF3 (80 µg/ml); E, QHF4 (160 µg/ml).

on the ability of HepG2 cells to migrate. Compared with the control group, the number of cells migrating was significantly different in the groups exposed to various concentrations of QHF ($P < 0.05$) (Fig. 2).

QHF inhibits the invasion of HepG2 cells. The cell invasion assay results were consistent with the migration assay results.




Figure 7. QHF affects the invasive ability of liver cancer cells following treatment with ERK (PD98059), p38 (SB203580) and the JNK (SP600125) inhibitors (stain, crystal violet; magnification, x200). (A) Control, (B) QHF4 group (160 µg/ml), (C) QHF4 + SP600125, (D) QHF4 + SB203580, (E) QHF4 + PD98059.

Compared with the control group, QHF significantly reduced the number of HepG2 cells migrating through the membrane filter ($P < 0.05$ or $P < 0.01$), and the invasive inhibition rate increased with the increase in QHF concentration. Thus, QHF exhibited marked inhibitory activity against the invasive ability of HepG2 cells in a concentration-dependent manner. A statistically significant difference was detected in cell number between the various QHF concentrations (QHF1-3: 20, 40 and 80 µg/ml) ($P < 0.05$) (Fig. 3).

Effects of QHF on liver cancer metastasis are associated with MAPK. Using western blot analysis, it was demonstrated that,

at 24 h after intervention, the expression levels of p-ERK were decreased significantly in the HepG2 cells treated with QHF compared with those in the control group cells, in a concentration-dependent manner ($P < 0.05$); however, differences in the expression of ERK protein between the different experimental groups were not always detected. Overall the results suggest that QHF inhibits the ERK signaling pathway (Fig. 4).

The results of western blot analysis showed that the expression levels of p-p38 and p-JNK were significantly increased in the HepG2 cells exposed to QHF for 24 h compared with those in the control group cells, in a concentration-dependent manner ($P < 0.05$); however, the total expression levels of p38 and JNK protein in each group were not obviously altered. The results indicate that QHF is able to activate the p38 and JNK signaling pathways (Figs. 5 and 6).

Effect of ERK, p38 and JNK inhibitors on the QHF-mediated inhibition of liver cancer cell invasion. PD98059 is an ERK-specific inhibitor that blocks the ERK signaling pathway. SB203580 is a specific p38 inhibitor that is able to inhibit p38 activity by blocking p38 signaling pathways. SP600125 specifically inhibits the actions of JNK by blocking the JNK signaling pathway. The results of the cell invasion experiments indicated that, following the blockage of the ERK pathway, the activity of the ERK pathway was decreased significantly compared with that in the cells treated solely with QHF (15 ± 3.54 vs. 25 ± 4.12 ; $P < 0.05$). ERK inhibitors thus appear to enhance the ability of QHF to inhibit liver cancer cell invasion. After blocking p38, and therefore the JNK signaling pathway, the number of cells passing through the membrane filters was increased significantly compared with the cells treated with QHF alone (53 ± 7.84 (QHF4 + SB203580) vs. 25 ± 4.12 (QHF4), 45 ± 8.92 (QHF4 + PD98059) vs. 25 ± 4.12). This difference was statistically significant ($P < 0.01$) indicating that the inhibition of liver cancer cell invasion by QHF is partially reversed by the p38 and JNK inhibitors (Fig. 7).

Discussion

HCC is among the most common malignant tumors worldwide and has a high mortality rate; however, recurrence and metastasis are the most crucial determining factors for HCC prognosis. According to clinical statistics, ~13 million individuals succumb to liver cancer in China each year, accounting for ~45% of liver cancer mortality worldwide (6). The 5-year recurrence rate of HCC remains as high as 61.5%, even following radical resection (7); thus, metastasis is a serious therapeutic challenge. The invasion and metastasis of HCC cells is a complicated, multi-step process mediated by numerous factors, including reactions between tumor cells and host cells involved in tumor cell adhesion, the secretion of matrix metalloproteinases (MMPs), degradation of the extracellular matrix, the migration of tumor cells, tumor angiogenesis, tumor cell proliferation and metastasis formation.

MAPK is a serine/threonine protein kinase that is widespread in cells. Three primary MAPK signal transduction pathways have been identified in mammals: ERK, p38 and JNK. These pathways extensively regulate cells and are involved in the generation of extracellular signals that affect nuclear reactions, in addition to serving a crucial function in

tumorigenesis, apoptosis and metastasis (8). Johansson *et al* (9) found that the p38-MAPK pathway was involved in squamous cell transformation and invasion. The ERK pathway is vital for the comprehensive regulation of cell growth, development and cell division, processes that mediate tumor development. Liang *et al* (10) and Kadowaki *et al* (11) showed that curcumin and tetrahydrocurcumin were able to affect the occurrence and development of HepG2 cells by inhibiting the expression of ERK in metastatic tumors in a nude mouse model. Furthermore, it has previously been indicated that ERK is able to promote extracellular matrix degradation and tumor angiogenesis by enhancing the proliferation of liver cancer cells or increasing the expression of MMP-2 and MMP-9, and this may be involved in the recurrence and metastasis of liver cancer (11). Numerous studies have shown that JNK is involved in the development of liver tumors; excessive activation of the JNK signaling pathway may affect normal liver cell proliferation and differentiation and lead to cancer (12-14). Win *et al* (12), who studied the effects of the mitochondrial protease SH3 domain-binding protein that preferentially associates with BTK (Sab) on liver cancer cells, observed that the continuous activation of JNK played a significant role in metastatic liver cancer cells and that the mitochondrial protease Sab had the ability to inhibit the activity of JNK.

The results of the present study suggest that the TCM formula QHF inhibited the proliferation of HepG2 cells and decreased their ability to invade and metastasize. Furthermore, QHF appeared to downregulate the expression of p-ERK and inhibit ERK signaling, while upregulating the expression of p-p38 and p-JNK and activating p38 and JNK signaling. The total ERK, p38 and JNK protein levels remained unchanged following treatment with inhibitors of ERK, p38 and JNK. The cell invasion assay indicated that the ERK inhibitor and QHF produced synergistic effects, while the JNK and p38 inhibitors partially reversed the QHF-mediated inhibition of liver cancer cell metastasis. These results suggest that the MAPK signaling pathway is associated with the QHF-mediated inhibition of HepG2 cell metastasis; however, the identification of specific downstream molecular targets requires further research.

The invasion and metastasis of HCC are complicated processes, both in terms of the complex biological characteristics of HCC and the close association between HCC and immune function, such as immune regulation and immune destructive capability. The present study indicates that QHF has the ability to significantly inhibit liver cancer invasion; therefore, QHF may represent a useful secondary pharmacological clinical treatment for liver cancer, which could improve the therapeutic outcomes of existing interventions.

Acknowledgements

This study was supported by a grant from the project of the Natural Science Foundation of Hubei (no. 2011CDA039).

References

1. Chen T, Li D, Fu YL and Hu W: Screening of QHF formula of effective ingredients from Chinese herbs and its anti-hepatic cell cancer effect in combination with chemotherapy. *Chinese Medical J (Engl)* 121: 363-368, 2008.

2. Tao C, Dan L, Ling F and Peng G: In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma. *J Biomed Res* 24: 161-168, 2010.
3. Cong H and Bin H: Effect of traditional Chinese medicine and the active ingredients on apoptosis of liver cells. *Zhong Yi Yao Za Zhi* 29: 24-26, 2001.
4. Chen T, Fu YL and Gong ZP: QHF compound in combination with small dose of cisplatin inhibit angiogenesis in H22 liver cancer mice. *Shi Jie Chang Wei Bing Xue Za Zhi* 18: 113-118, 2010.
5. Chen T, Fu YL, Gong ZP, Deng LR and Hu YG: Studies on the anti-angiogenic mechanism of the formula of Chinese medicine active ingredients combined with small dose cisplatin in mice of hepatocellular carcinoma. *Zhong Guo Shi Yan Fang Ji Xue Za Zhe She* 16: 157-160, 2010 (In Chinese).
6. Xie HJ: Experimental study on the status and prospects of the mechanism of traditional Chinese medicine treatment of liver cancer. *J Chin Med Res* 22: 62-64, 2009 (In Chinese).
7. Sun HC: Advances in the treatment of postoperative metastasis and recurrence of liver cancer. *Ai Zheng Jin Zhan Za Zhe Shi* 3: 30-32, 2005 (In Chinese).
8. Song MK, Kim YJ, Song M, Choi HS, Park YK and Ryu JC: Polycyclic aromatic hydrocarbons induce migration in human hepatocellular carcinoma cells (HepG2) through reactive oxygen species-mediated p38 MAPK signal transduction. *Cancer Sci* 102: 1636-1644, 2011.
9. Johansson N, Ala-aho R, Uitto V, Grénman R, Fusenig NE, López-Otín C and Kähäri VM: Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. *J Cell Sci* 113: 227-235, 2000.
10. Liang J, Bao C, Wei J and Su RJ: The expression and significance of p38 and ERK1/2 in hepatocellular carcinoma. *Zhong Guo Zu Zhi Hua Xue Yu Xi Bao Hua Xue Za Zhi* 18: 202-205, 2009 (In Chinese).
11. Kadowaki S, Endoh D, Okui T and Hayashi M: Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells by activation of the p38 MAPK pathway. *J Vet Med Sci* 71: 1541-1544, 2009.
12. Win S, Than TA, Han D, Petrovic LM and Kaplowitz N: c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab expression in mice. *J Biol Chem* 286: 35071-35078, 2011.
13. Gozdecka M, Lyons S, Kondo S, Taylor J, Li Y, Walczynski J, Thiel G, Breitwieser W and Jones N: JNK suppresses tumor formation via a gene-expression program mediated by ATF2. *Cell Rep* 9: 1361-1374, 2014.
14. Hsieh SC, Tsia JP, Yang SF, Tang MJ and Hsieh YH: Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF- κ B dependent pathway that reduces uPA and MMP-9 expression. *Amino Acids* 46: 2809-2822, 2014.

RETRACTED